Show Cart

Antibodies

23 May 2018 F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody
23 May 2018 Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
23 May 2018 Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform
23 May 2018 Apogenix Provides Update on Clinical Development of Asunercept
23 May 2018 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial
23 May 2018 Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration
23 May 2018 Efficacy and safety of Cytotect® CP was demonstrated in patients after stem cell transplantation
22 May 2018 CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
22 May 2018 FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
22 May 2018 Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III Haven 3 Study in Hemophilia A Without Factor VIII Inhibitors
18 May 2018 Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
17 May 2018 Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus
17 May 2018 Innovent Biologics Announces the Study Result of its Anti-PD-1 Antibody in Hodgkin Lymphoma
17 May 2018 Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer
17 May 2018 Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)
17 May 2018 Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
17 May 2018 Phase III IMpower150 Study Showed Genentech's TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel
16 May 2018 CIMZIA® (certolizumab pegol) is The First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
16 May 2018 Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
16 May 2018 GT Biopharma Announces Update to OXS-3550 IND Filing, Its Most Advanced Tri-specific Killer Engager
16 May 2018 Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
15 May 2018 Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
15 May 2018 Oncternal Opens its CIRLL Study, a Combination Trial of Cirmtuzumab with Ibrutinib in B-Cell Malignancies
15 May 2018 Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15 May 2018 FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis

Currencies

Shopping cart

Cart empty

Latest report

Featured Products

Recommended Report

Currencies

Shopping cart

Cart empty

Latest report

Featured Products

Recommended Report

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top